

# Jeff Gershenwald

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9345304/jeff-gershenwald-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318  
papers

39,060  
citations

85  
h-index

195  
g-index

374  
ext. papers

47,242  
ext. citations

11.1  
avg, IF

6.74  
L-index

#	Paper	IF	Citations
318	Final version of 2009 AJCC melanoma staging and classification. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6199-206	2.2	3512
317	Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3635-48	2.2	2173
316	Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3622-34	2.2	2077
315	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , <b>2018</b> , 359, 97-103	33.3	1895
314	The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2017</b> , 67, 93-99	220.7	1819
313	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , <b>2015</b> , 161, 1681-96	56.2	1807
312	A landscape of driver mutations in melanoma. <i>Cell</i> , <b>2012</b> , 150, 251-63	56.2	1799
311	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2017</b> , 67, 472-492	220.7	1044
310	Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 976-83	2.2	1039
309	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , <b>2016</b> , 6, 202-16	24.4	841
308	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2211-2222	59.2	739
307	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , <b>2020</b> , 577, 549-555	50.4	654
306	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , <b>2016</b> , 6, 827-37	24.4	561
305	NRAS mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , <b>2012</b> , 118, 4014-23	6.4	483
304	Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 2253-60	2.2	478
303	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	409
302	Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 751-61	4.5	409

301	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 204-220.e15	24.3	391
300	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. <i>Nature Genetics</i> , <b>2011</b> , 43, 442-6	36.3	385
299	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , <b>2018</b> , 24, 1649-1654	50.5	377
298	A new American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Cancer</i> , <b>2000</b> , 88, 1484-91	6.4	331
297	Activation of stat3 in human melanoma promotes brain metastasis. <i>Cancer Research</i> , <b>2006</b> , 66, 3188-96	10.1	330
296	Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2452-9	2.2	320
295	Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6758-70	12.8	291
294	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 310-322	21.7	284
293	Melanoma. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15003	51.1	283
292	An evidence-based staging system for cutaneous melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2004</b> , 54, 131-49; quiz 182-4	220.7	270
291	Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. <i>American Journal of Pathology</i> , <b>1997</b> , 151, 1105-13	5.8	258
290	Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2199-205	2.2	250
289	Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 129-42	9.7	219
288	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2016</b> , 66, 370-4	220.7	219
287	A novel AKT3 mutation in melanoma tumours and cell lines. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1265-8	8.7	214
286	Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. <i>Annals of Surgical Oncology</i> , <b>2001</b> , 8, 192-7	3.1	207
285	Clinical correlates of NRAS and BRAF mutations in primary human melanoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 229-35	12.9	206
284	Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 208-250	4.5	202

283	Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. <i>Annals of Surgical Oncology</i> , <b>2000</b> , 7, 160-5	3.1	200
282	Ethnic differences among patients with cutaneous melanoma. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1907-14		195
281	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7538-7546	12.9	184
280	Phase II trial of imatinib mesylate in patients with metastatic melanoma. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 734-40	8.7	181
279	Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2851-5	2.2	180
278	Lessons learned from the Sunbelt Melanoma Trial. <i>Journal of Surgical Oncology</i> , <b>2004</b> , 86, 212-23	2.8	179
277	Interleukin 1 receptor blockade attenuates the host inflammatory response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 4966-70	11.5	177
276	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 181-193	21.7	168
275	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. <i>Surgery</i> , <b>1998</b> , 124, 203-210	3.6	168
274	Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. <i>Annals of Surgical Oncology</i> , <b>2005</b> , 12, 587-96	3.1	167
273	Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4296-303	2.2	165
272	Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 5012-23	5.6	164
271	Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. <i>Annals of Surgical Oncology</i> , <b>1998</b> , 5, 322-8	3.1	164
270	Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. <i>Annals of Surgical Oncology</i> , <b>2003</b> , 10, 569-74	3.74	164
269	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. <i>Nature Cell Biology</i> , <b>2015</b> , 17, 311-21	23.4	155
268	Invasive squamous cell carcinoma of the skin: defining a high-risk group. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 902-9	3.1	149
267	Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 809-16	3.1	130
266	Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 308-15	9.7	129

265	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 13481-6	11.5	127
264	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , <b>2019</b> , 9, 628-645	24.4	124
263	Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 16501-8	5.4	120
262	Age as a prognostic factor in patients with localized melanoma and regional metastases. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3961-8	3.1	118
261	Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 4555-8	2.2	117
260	Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. <i>Nature Genetics</i> , <b>2011</b> , 43, 1119-26	36.3	116
259	Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 712-20	3.1	116
258	Staging and prognosis of cutaneous melanoma. <i>Surgical Oncology Clinics of North America</i> , <b>2011</b> , 20, 1-17.	7.7	115
257	Organization of the AJCC Cancer Staging Manual <b>2017</b> , 31-37		115
256	Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	114
255	Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2764-72	3.1	112
254	Sentinel node biopsy and standard of care for melanoma. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 872-5	4.5	107
253	Sentinel-lymph-node biopsy for cutaneous melanoma. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1738-45	5.2	104
252	Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5527-36	12.9	103
251	Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 104, 379-85	2.8	102
250	Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 1075-81	3.1	101
249	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 508-515	4.3	99
248	Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. <i>Annals of Surgical Oncology</i> , <b>2001</b> , 8, 766-70	3.1	98

247	The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4588-90	2.2	97
246	Structure function relationships in the lymphatic system and implications for cancer biology. <i>Cancer and Metastasis Reviews</i> , <b>2006</b> , 25, 159-84	9.6	95
245	State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2016</b> , 66, 460-480	220.7	93
244	Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 637-643	4.5	92
243	Contralateral prophylactic mastectomy. Predictors of significant histologic findings. <i>Cancer</i> , <b>2004</b> , 101, 1977-86	6.4	92
242	Adjuvant irradiation for axillary metastases from malignant melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 52, 964-72	4	91
241	New TNM melanoma staging system: linking biology and natural history to clinical outcomes. <i>Journal of Surgical Oncology</i> , <b>2003</b> , 21, 43-52		90
240	Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. <i>Cancer</i> , <b>2006</b> , 106, 900-6	6.4	89
239	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e378-e389	21.7	88
238	Metastatic melanoma to lymph nodes in patients with unknown primary sites. <i>Cancer</i> , <b>2006</b> , 106, 2012-2014	20.4	88
237	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , <b>2016</b> , 14, 168	11.4	87
236	Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2006-14	3.1	87
235	Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 709-17	3.1	84
234	Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. <i>JAMA Otolaryngology</i> , <b>2006</b> , 132, 370-3		84
233	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , <b>2017</b> , 2,	6.2	82
232	Role of sentinel lymph node biopsy in patients with thin melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 308-17	7.3	81
231	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 775-784	3.5	81
230	Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. <i>Cancer</i> , <b>2013</b> , 119, 3821-9	6.4	79

229	CpG island methylation profiling in human melanoma cell lines. <i>Melanoma Research</i> , <b>2009</b> , 19, 146-55	3.3	79
228	Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6709-15	12.9	79
227	Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6054-62	2.2	78
226	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1861-1868	10.3	77
225	Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. <i>Cancer</i> , <b>2006</b> , 107, 2647-52	6.4	75
224	Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2858-65	2.2	75
223	Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. <i>Cancer</i> , <b>2002</b> , 95, 354-60	6.4	74
222	Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 2526-32	4	73
221	Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. <i>Carcinogenesis</i> , <b>2006</b> , 27, 1894-901	4.6	72
220	Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3593-600	3.1	68
219	Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. <i>Oncogene</i> , <b>2001</b> , 20, 3363-75	9.2	68
218	Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. <i>Journal of Cutaneous Pathology</i> , <b>2009</b> , 36, 1157-63	1.7	66
217	Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. <i>Cancer</i> , <b>2010</b> , 116, 2234-41	6.4	66
216	Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. <i>Annals of Surgical Oncology</i> , <b>2000</b> , 7, 256-61	3.1	66
215	Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. <i>Annals of Surgery</i> , <b>2011</b> , 253, 1211-5	7.8	65
214	Combined-modality therapy for patients with regional nodal metastases from melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 106-13	4	65
213	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 404-16	4.5	63
212	Biology of advanced uveal melanoma and next steps for clinical therapeutics. <i>Pigment Cell and Melanoma Research</i> , <b>2015</b> , 28, 135-47	4.5	62



211	Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. <i>Cancer Research</i> , <b>2005</b> , 65, 11185-92	10.1	62
210	Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 18637-42	11.5	60
209	A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. <i>Cancer Research</i> , <b>2008</b> , 68, 8419-28	10.1	60
208	Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. <i>Cancer</i> , <b>2008</b> , 112, 2249-57	6.4	60
207	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. <i>Cancer</i> , <b>2004</b> , 100, 383-9	6.4	59
206	Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1079-86	2.2	58
205	Melanoma of the Skin <b>2017</b> , 563-586		58
204	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4416-4428	12.9	58
203	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , <b>2021</b> , 27, 1432-1441	50.5	57
202	Melanoma adrenal metastasis: natural history and surgical management. <i>American Journal of Surgery</i> , <b>2008</b> , 195, 363-8; discussion 368-9	2.7	56
201	C-reactive protein as a marker of melanoma progression. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1389-96	2.2	55
200	A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. <i>Annals of Surgical Oncology</i> , <b>2004</b> , 11, 1079-84	3.1	55
199	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , <b>2021</b> , 374, 1632-1640	33.3	52
198	Lymph node ratio predicts disease-specific survival in melanoma patients. <i>Cancer</i> , <b>2009</b> , 115, 2505-13	6.4	51
197	Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. <i>Journal of Infectious Diseases</i> , <b>1992</b> , 165, 859-64	7	51
196	Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). <i>World Journal of Surgical Oncology</i> , <b>2008</b> , 6, 63	3.4	50
195	Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 2867-75	3.1	50
194	Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1741-7	2.2	49



193	Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. <i>Annals of Surgical Oncology</i> , <b>2000</b> , 7, 226-31	3.1	49
192	Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 2077-84	7.5	47
191	Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. <i>Human Mutation</i> , <b>2008</b> , 29, 1443-51	4.7	46
190	Cancer. Targeting lymphatic metastasis. <i>Science</i> , <b>2002</b> , 296, 1811-2	33.3	45
189	A highly recurrent RPS27 5'UTR mutation in melanoma. <i>Oncotarget</i> , <b>2014</b> , 5, 2912-7	3.3	45
188	Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , <b>2007</b> , 127, 276-80	4.3	44
187	Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. <i>Annals of Surgical Oncology</i> , <b>2003</b> , 10, 348-54	3.1	44
186	In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1822-31	9.7	44
185	Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. <i>Clinical Radiology</i> , <b>2011</b> , 66, 224-36	2.9	43
184	Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4882-91	12.9	43
183	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncotarget</i> , <b>2016</b> , 5, e1136044	7.2	42
182	Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. <i>Journal of Investigative Dermatology</i> , <b>2007</b> , 127, 387-93	4.3	42
181	Evidence-based treatment of early-stage melanoma. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 104, 341-53	2.8	41
180	Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. <i>Molecular Cancer Research</i> , <b>2010</b> , 8, 1513-25	6.6	41
179	Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. <i>Neoplasia</i> , <b>2010</b> , 12, 173-82	6.4	40
178	Polymorphisms of nucleotide excision repair genes predict melanoma survival. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 1813-21	4.3	39
177	Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 253-63	1.9	39
176	p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 121, 1510-4	4.3	39

175	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2093-2104	12.9	37
174	Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. <i>Melanoma Research</i> , <b>2012</b> , 22, 376-85	3.3	37
173	Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. <i>Melanoma Research</i> , <b>2013</b> , 23, 290-7	3.3	36
172	Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. <i>Value in Health</i> , <b>2011</b> , 14, 900-6	3.3	36
171	How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 670-3	3.1	36
170	How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? <i>Surgery</i> , <b>2000</b> , 128, 306-11	3.6	36
169	Critical Assessment of Clinical Prognostic Tools in Melanoma. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2753-61	3.6	36
168	Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. <i>Annals of Surgery</i> , <b>2014</b> , 259, 1215-22	7.8	35
167	Imaging studies in patients with melanoma. <i>Surgical Oncology Clinics of North America</i> , <b>2007</b> , 16, 403-30	2.7	35
166	Human melanoma cytotoxicity by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. <i>Cancer Research</i> , <b>2008</b> , 68, 4392-7	10.1	34
165	Melanoma pathology reporting and staging. <i>Modern Pathology</i> , <b>2020</b> , 33, 15-24	9.8	34
164	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , <b>2015</b> , 46, 1101-10	3.7	33
163	A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. <i>Melanoma Research</i> , <b>2009</b> , 19, 42-9	3.3	33
162	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. <i>Surgery</i> , <b>1998</b> , 124, 203-10	3.6	33
161	Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 73, 1376-82	4	32
160	Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. <i>Annals of Surgery</i> , <b>2020</b> , 272, e144-e147	7.8	32
159	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3016-24	12.9	31
158	Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3611-20	12.9	31

157	Lymphangiogenesis and hemangiogenesis: potential targets for therapy. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 489-500	2.8	30
156	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2719-2727	2.2	29
155	Clinicopathological features and clinical outcomes associated with TP53 and BRAF mutations in cutaneous melanoma patients. <i>Cancer</i> , <b>2017</b> , 123, 1372-1381	6.4	28
154	Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. <i>Annals of Surgical Oncology</i> , <b>1998</b> , 5, 529-38	3.1	28
153	Classification and staging of melanoma. <i>Hematology/Oncology Clinics of North America</i> , <b>1998</b> , 12, 737-653.1		28
152	Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. <i>Journal of the American College of Surgeons</i> , <b>2005</b> , 201, 821-3; author reply 823-4	4.4	28
151	Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3073	1.8	28
150	Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 2170-81	5.8	27
149	Cutaneous melanoma: a model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 538-498		27
148	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 1792-1795	4.3	26
147	Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. <i>European Journal of Cancer Care</i> , <b>2015</b> , 24, 724-33	2.4	26
146	Principles of Cancer Staging <b>2017</b> , 3-30		26
145	Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. <i>Cancer Medicine</i> , <b>2018</b> , 7, 583-593	4.8	25
144	Sentinel lymph node biopsy in melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2012</b> , 18, 185-91	2.2	25
143	Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2015-23	3.1	25
142	Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. <i>Annals of Surgical Oncology</i> , <b>2001</b> , 8, 116-22	3.1	25
141	A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. <i>Journal of the American College of Surgeons</i> , <b>2012</b> , 214, 608-17; discussion 617-9	4.4	24
140	Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , <b>2008</b> , 128, 1585-8	4.3	24

139	Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. <i>Melanoma Research</i> , <b>2003</b> , 13, 379-87	3.3	24
138	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1886-1895	12.9	24
137	Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 1004-1011	5.1	24
136	Principles of Melanoma Staging. <i>Cancer Treatment and Research</i> , <b>2016</b> , 167, 131-48	3.5	23
135	Cost effectiveness of adjuvant interferon in node-positive melanoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2442-8	2.2	23
134	Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. <i>Neoplasia</i> , <b>2006</b> , 8, 747-57	6.4	23
133	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , <b>2020</b> , 16, 4429-4438	3.6	23
132	Lymphatic mapping in the molecular era. <i>Annals of Surgical Oncology</i> , <b>2004</b> , 11, 362-74	3.1	22
131	The new melanoma staging system. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2003</b> , 22, 42-54	1.4	22
130	Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. <i>Cancer</i> , <b>2007</b> , 109, 1570-8	6.4	21
129	Adverse events associated with the intraoperative injection of isosulfan blue. <i>Journal of Clinical Anesthesia</i> , <b>2004</b> , 16, 332-41	1.9	21
128	Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. <i>Clinics in Dermatology</i> , <b>2013</b> , 31, 298-310	3	20
127	Improving the quality of cancer staging. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2015</b> , 65, 261-3	220.7	20
126	Targeted therapy for melanoma: a primer. <i>Surgical Oncology Clinics of North America</i> , <b>2011</b> , 20, 165-80	2.7	19
125	Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. <i>Cancer</i> , <b>2008</b> , 112, 2030-7	6.4	19
124	The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. <i>Oncotarget</i> , <b>2012</b> , 3, 336-44	3.3	19
123	The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 112, 834-40	2.8	18
122	Randomized controlled trial of a sun protection intervention for children of melanoma survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 1813-24	4	18

121	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 1314-1322	9.7	17
120	FOXD3 Regulates VISTA Expression in Melanoma. <i>Cell Reports</i> , <b>2020</b> , 30, 510-524.e6	10.6	17
119	Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. <i>Surgical Oncology Clinics of North America</i> , <b>2011</b> , 20, 57-78	2.7	17
118	Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3008-3008	2.2	17
117	Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 2352-2358.e3	4.3	15
116	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , <b>2019</b> , 125, 18-44	6.4	15
115	Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 88-100	7.1	15
114	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. <i>Surgery</i> , <b>2017</b> , 161, 1246-1254	3.6	14
113	Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors. <i>American Journal of Preventive Medicine</i> , <b>2016</b> , 51, e77-85	6.1	14
112	Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 452-460	4.3	14
111	Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. <i>Clinical and Experimental Metastasis</i> , <b>2008</b> , 25, 191-9	4.7	14
110	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. <i>Annals of Oncology</i> , <b>2007</b> , 18, 806-8	10.3	14
109	Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. <i>Surgical Oncology</i> , <b>2020</b> , 34, 182-185	2.5	13
108	Semiconductor-based DNA sequencing of histone modification states. <i>Nature Communications</i> , <b>2013</b> , 4, 2672	17.4	13
107	Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 2521-6	11.5	13
106	Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. <i>Melanoma Research</i> , <b>2012</b> , 22, 169-75	3.3	13
105	Is sentinel-node biopsy superior to nodal observation in melanoma?. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 278-9		13
104	Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> ,	7.1	13

103	Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	13
102	ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. <i>Cancer Research</i> , <b>2018</b> , 78, 5680-5693	10.1	12
101	Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. <i>BioMed Research International</i> , <b>2013</b> , 2013, 898719	3	12
100	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7585-7593	12.9	12
99	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2678-2697	12.9	11
98	Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 2172-2177	3.1	10
97	Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. <i>JAMA Dermatology</i> , <b>2017</b> , 153, 228-229	5.1	10
96	Promoter polymorphisms in matrix metalloproteinase 1 and risk of cutaneous melanoma. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 107-115	7.5	10
95	Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 8500-8500	2.2	10
94	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1429-1441	2.2	9
93	Gene expression profiling of human cutaneous melanoma: are we there yet?. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 121-3	4.6	9
92	Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy <b>2016</b> ,		9
91	CDC Grand Rounds: Prevention and Control of Skin Cancer. <i>Morbidity and Mortality Weekly Report</i> , <b>2015</b> , 64, 1312-4	31.7	9
90	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , <b>2020</b> , 33, 496-513	9.8	9
89	Enforcement Provisions of Indoor Tanning Bans for Minors: An Analysis of the First 6 US States. <i>American Journal of Public Health</i> , <b>2015</b> , 105, e10-2	5.1	8
88	The new staging system for cutaneous melanoma in the era of lymphatic mapping. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 415-25	5.5	8
87	Surgical clinical trials in melanoma. <i>Surgical Clinics of North America</i> , <b>2003</b> , 83, 385-403	4	8
86	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1569-1579	10.3	8



85	A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 118, 922-927	2.8	8
84	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 875-885	9.7	7
83	Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. <i>American Journal of Roentgenology</i> , <b>2006</b> , 187, W117-9	5.4	7
82	Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. <i>European Journal of Surgical Oncology</i> , <b>2005</b> , 31, 323-4	3.6	7
81	Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 1894-1897	4.3	6
80	Prognostic significance of the sentinel lymph node (SLN) in stage I or II melanoma patients. <i>Melanoma Research</i> , <b>1997</b> , 7, S105	3.3	6
79	A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9582-9582	2.2	6
78	Tissue resources for clinical use and marker studies in melanoma. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1102, 679-95	1.4	6
77	Clinical classification and staging. <i>Clinics in Plastic Surgery</i> , <b>2000</b> , 27, 361-76, viii	3	6
76	Classification and staging of melanoma. <i>Clinics in Laboratory Medicine</i> , <b>2000</b> , 20, 785-815	2.1	6
75	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 2266-2272	4.3	5
74	Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. <i>Cancer</i> , <b>2020</b> , 126, 775-781	6.4	5
73	Role of Elevated Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4119-4125	12.9	5
72	Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, e27-e28	4.5	4
71	Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1913-1914	27.4	4
70	4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. <i>Melanoma Research</i> , <b>2016</b> , 26, 181-7	3.3	4
69	Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. <i>Pigment Cell and Melanoma Research</i> , <b>2013</b> , 26, 422-5	4.5	4
68	Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 8516-8516	2.2	4



67	Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9014-9014	2.2	4
66	A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 101-109	4	4
65	CDC Grand Rounds: Prevention and Control of Skin Cancer. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 717-720	8.7	4
64	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 101	8.5	3
63	Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome <b>2017</b> ,		3
62	Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application <b>2018</b> ,		3
61	Microscopic tumor burden in sentinel lymph nodes (SLNs) best predicts nonsentinel lymph node (NSLN) involvement in patients with melanoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 8004-8004	2.2	3
60	Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4,895 melanoma patients. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 9035-9035	2.2	3
59	Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9579-9579	2.2	3
58	Relapse-free survival and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9587-9587	2.2	3
57	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS9596-TPS9596	2.2	3
56	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8650-8661	4.8	3
55	Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing. <i>JCO Clinical Cancer Informatics</i> , <b>2019</b> , 3, 1-11	5.2	3
54	Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1442-1444	6.7	3
53	Skin Cancer: Have melanoma and skin cancer finally met their match?. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 267-268	19.4	2
52	Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 2667-2674	3.1	2
51	Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 253-257	4.3	2
50	The relationship between blood IL-12p40 level and melanoma progression. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1874-80	7.5	2

49	Nodal failure after lymphatic mapping (LM) and negative sentinel lymph node (SLN) biopsy in stage I or II melanoma patients. <i>Melanoma Research</i> , <b>1997</b> , 7, S29	3.3	2
48	Radiation Treatment Field Delineation for Axillary Metastases from Malignant Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, S105-S106	4	2
47	Management of early-stage cutaneous melanoma. <i>Current Problems in Surgery</i> , <b>2005</b> , 42, 460-534	2.8	2
46	Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 8581-8581	2.2	2
45	A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS9594-TPS9594	2.2	2
44	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. <i>OncImmunity</i> , <b>2021</b> , 10, 1992880 <sup>2</sup>	7.2	2
43	Functional annotation of melanoma risk loci identifies novel susceptibility genes. <i>Carcinogenesis</i> , <b>2020</b> , 41, 452-457	4.6	2
42	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , <b>2021</b> , 11, 9043	4.9	2
41	Staging of Cutaneous Melanoma: Is There Room for Further Improvement?. <i>JAMA Network Open</i> , <b>2018</b> , 1, e180086	10.4	2
40	Sentinel Lymph Node Biopsy in Cutaneous Melanoma <b>2008</b> , 92-110		2
39	A lupus-like reaction to subcutaneous interferon- $\beta$ injection sites. <i>Journal of Drugs in Dermatology</i> , <b>2012</b> , 11, 393-8	2.2	2
38	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	2
37	Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.. <i>Annals of Surgical Oncology</i> , <b>2022</b> ,	3.1	2
36	Reply to J.M. Thomas et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e480-e481	2.2	1
35	Fellowship training in surgical oncology--an international affair. <i>Surgical Oncology</i> , <b>2008</b> , 17, 277-9	2.5	1
34	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	1
33	Impact of comorbidities on overall survival of high-risk and advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8536-8536	2.2	1
32	Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9543-9543	2.2	1

31	Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes <b>2001</b> , 8, 116		1
30	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , e320-e325	7.1	1
29	Melanoma Prognosis and Staging <b>2020</b> , 271-297		1
28	Melanoma Prevention and Screening <b>2019</b> , 1-46		1
27	Melanoma Prevention and Screening <b>2020</b> , 525-570		1
26	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 3480-3489 <sup>1</sup>		1
25	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 142	8.5	1
24	Be Well Communities—mobilizing communities to promote wellness and stop cancer before it starts. <i>Cancer Causes and Control</i> , <b>2021</b> , 32, 859-870	2.8	1
23	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 171	8.5	1
22	Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2021</b> , 145, 1505-1515	5	1
21	Cutaneous Melanoma <b>2013</b> , 153-165		1
20	Risk Models for Individualized Prognosis in the Practice of Precision Oncology <b>2017</b> , 47-52		0
19	Updates in the evidence-based management of cutaneous melanoma. <i>Head and Neck</i> , <b>2020</b> , 42, 3396-3404	4.4	0
18	Staging and Classification of Melanoma <b>2018</b> , 87-103		
17	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , <b>2018</b> , 40, 831-835	0.9	
16	Melanoma Clinical Staging (Historical and Current) <b>2019</b> , 485-500		
15	Lymphatic Mapping and Sentinel Lymph Node Biopsy 501-515		
14	HLA class II alleles predict recurrence and pattern of failure in early-stage melanoma patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 8503-8503	2.2	

- 13 Stage at presentation to determine associations between histologic parameters of primary tumor and disease specific survival (DSS) in anorectal melanoma (AM).. *Journal of Clinical Oncology*, **2018**, 36, e21622-e21622 2.2
- 12 Models for Predicting Melanoma Outcome **2019**, 1-16
- 11 Melanoma Prognosis and Staging **2019**, 1-27
- 10 Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. *Journal of Clinical Oncology*, **2019**, 37, TPS145-TPS145 2.2
- 9 Models for Predicting Melanoma Outcome **2020**, 299-314
- 8 Do patient-reported quality-of-life responses in melanoma patients vary by stage?. *Journal of Clinical Oncology*, **2014**, 32, e20007-e20007 2.2
- 7 Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (muts).. *Journal of Clinical Oncology*, **2016**, 34, 9535-9535 2.2
- 6 Melanoma Clinical Staging (Historical and Current) **2018**, 1-16
- 5 Therapeutic Targeting of the Lymphovascular System in Cancer: Promise and Challenge **2009**, 191-199
- 4 Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy. *Journal of Clinical Oncology*, **2009**, 27, 3021-3021 2.2
- 3 Quantitative assessment of AKT activation in melanoma. *Journal of Clinical Oncology*, **2009**, 27, 9022-9022 2.2
- 2 Prognostic Factors and Staging in Melanoma **2011**, 282-294
- 1 The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. *Journal of Translational Medicine*, **2022**, 20, 200 8.5